Apoptosis is an important area of research because of its role in keeping a mature multicellular organism's number of cells constant, hence, ensuring that the organism does not have cell accumulation that may transform into cancer with additional hallmarks. Firstly, we have carried out sensitivity analysis on an existing mathematical mitochondria-dependent apoptosis model to find out which parameters have a role in causing monostable cell survival, which may, in turn, lead to malfunction in apoptosis. We have then generated three base parameter sets that represent healthy cells. These parameter sets were built by changing the sensitive parameters while preserving the bistability. For each base set, we varied the proapoptotic and antiapoptotic production rates, to yield new sets for the cells that have malfunctioning apoptosis. In a hypothetical cell model, we simulated caspase-3 activation by numerically integrating the governing ordinary differential equations of a mitochondria-dependent apoptosis model. These simulations were carried out for four potential treatments, namely: (1) proteasome inhibitor treatment, (2) Bcl-2 inhibitor treatment, (3) IAP inhibitor treatment, (4) Bid-like synthetic peptides treatment. The results suggest that the proteasome inhibitor treatment is the most effective treatment, though it may have severe side effects. For this treatment, the amount of proteasome inhibitor needed for caspase-3 activation may be different for hypothetical cells with a different pro-or anti-apoptotic protein defect. It is also found that caspase-3 can be activated by Bcl-2 inhibitor treatment only in those hypothetical malfunctioning cells with Bax deficiency but not in others. These results are in line with the view that molecular heterogeneity in individuals may be an important factor in determining the individuals' positive or negative responses to treatments.
Introduction
Chemotherapy resistance is an important problem in cancer treatments. A specific cancer chemotherapy that is used on patients whose tumors have similar histopathology may have very different responses. Oncologists suspect that subsets of patients that respond positively to a chemotherapy are hidden in larger groups of resistant cases. Genetic and molecular heterogeneity may be the cause of these subsets [1] . The presence or absence of, or more specifically, the quantity of a biological molecule e.g., DNA, RNA, protein and other metabolites which indicate whether the individual is healthy or has a disease is a biomarker. Therefore, assessment of biomarkers can unravel this genetic and molecular heterogeneity and may be utilized to determine the type and the dosage of chemotherapeutic treatment.
Mathematical modeling followed by in silico computations may facilitate the decision of the chemotherapy method to be applied in clinical monitoring and care.
The beneficial effects of chemotherapy drugs can be mitotic catastrophe, apoptosis or prolonged cell cycle arrest. Hence, defects in apoptotic mechanisms may be a reason for chemotherapy resistance. The mitochondria-dependent apoptotic pathway is the major apoptotic pathway which is utilized by chemotherapeutic drugs [2] . There are two types of cells for apoptosis: Type I and Type II. If the apoptotic signaling pathway bypasses mitochondria then these are referred to as Type I cells otherwise Type II cells. While Type I cells can bypass mitochondria if mitochondrial outer membrane permeability (MOMP) is blocked, they will generally use MOMP if there is no block.
A mathematical model for mitochondria-dependent apoptosis, in which bistability emerges as healthy functioning of the Type II cells was proposed by Bagci et al. [3] . In this model, the extracellular apoptotic stimulus (Fas Ligand) results in cytochrome c (cyt c) release from the mitochondria and caspase-3 activation which is the executioner enzyme for apoptosis. For simplicity, the model excluded the reactions before caspase-8 formation. The detailed descriptions of the model can be found in Model and Methods section in Bagci et al. [3] .
The biochemical mechanism of apoptosis is studied extensively because of the importance of keeping the number of cells in the mature organism balanced in response to pro-or anti-apoptotic stimuli [4] . In healthy tissues, the cell number is maintained at around a constant level through the balance of cell proliferation and cell death rates. However, in malfunctioning apoptosis, the rate of cell proliferation can be higher (lower) than the rate of cell death and the number of cells increases (decreases). An experimental study of oxidative stress-induced apoptosis, although distinct from ligand-induced apoptosis that we have modeled, is studied by Nair et al. [5] who have examined a population of cells undergoing oxidative stress. The cells activated two types of responses, either cytoprotective or apoptotic. Their work supports the view that cell responses to pro-apoptotic signals are bistable. It is to be noted that according to Spencer and Sorger [6] , bistability is not the only mechanism that can cause a switch in cell fate, a monostable model that predicts a switch from cell survival to apoptosis in a temporal sense is also plausible. But we have, in our work, taken the other point of view that bistability is necessary for the switch and neither has yet superiority over the other.
In this study, by healthy cells, we mean the cells without apoptosis malfunction prior to any treatment. Parameter sets representing cells with apoptosis malfunction are obtained by decreasing the proapoptotic protein production rates or increasing the antiapoptotic production rates in the corresponding set. We call these cells ''hypothetical malfunctioning cells''. It is to be noted that these hypothetical malfunctioning cells can not represent all the tumor cells since some of the tumor cells may have apoptosis rates that are considerably higher than that of a normal cell [7] . The hypothetical malfunctioning cell model for a given parameter set is then simulated to see the effects of four different treatment methods. The cells are predicted to be resistant to treatment if apoptosis is not possible in the simulations. On the other hand, they are predicted to be sensitive to the treatment if apoptosis is induced.
After pioneering studies by Fussenegger et al. [8] and Eissing et al. [9] , many apoptosis models have been published (see review by Salvioli et al. [10] and other references [3, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] ). These studies and the present study are focused on molecular pathways. There are studies carried out at the cellular level [30] [31] [32] . However, to the best of our knowledge, none of the previous studies were focused on resistance to treatment for malfunction in apoptotic pathways. The results we have obtained suggest that the type of potential treatment and the identity of the deficient proapoptotic or overproduced antiapoptotic protein determine whether apoptosis will be induced in a hypothetical malfunctioning cell. Therefore, the results suggest that the reason of different outcomes of a treatment in different people may be the genetic variations in their cells causing differences in the production rates of apoptotic proteins [4] .The previous simulations by Bagci et al. [3] predicted a pathological state in which cells will exhibit a monostable cell survival if the degradation rate constant (expression rate constant) of the proapoptotic protein Bax is above (below) a threshold value. On the other hand, with suitable values of rate constants, the model predicts bistability with a suitable threshold of apoptotic stimulus for apoptosis. We used a mathematical model that was originally proposed by Bagci et al. [3] since this model predicts the normal functioning (bistable, healthy cell) and malfunctioning (monostable, unhealthy cell) of apoptosis. The reactions in the model are arranged in their order of occurrence so that the sequence obtained is causally related. In addition to this there should be positive feedback in the sequence of reactions (either in the form of up regulation or double down regulation in the reaction loop) for bistability Bagci et al. [3] and Sen et al. [33] . Herein, it is assumed that all pathways other than those related to apoptosis remain unchanged, and therefore a change in apoptosis will lead to a change in the number of cells. In this article, we first present the sensitivity analysis to determine the parameters to which caspase-3 activation is most sensitive. Then, we summarize the results of the sensitivity analysis performed on the model parameters. This is followed by presenting the simulations of four hypothetical potential treatments i.e., the proteasome inhibitor treatment, Bcl-2 and IAP inhibitors treatment and Bid-like synthetic peptides treatment of which proteasome inhibitor treatment is found to be the most effective. The results support the view that molecular heterogeneity among individuals may be a reason for varied responses to treatments. We also compared the predictions of our model with the experimental results compiled by di Pietro et al. [34] from several databases. It should be emphasized that our focus in this study is to devise treatment plans for patients with different defects (malfunction) in apoptosis and not the much more complicated problem, chemotherapy resistance to cancer [35] .
Methods
The model proposed in Bagci et al. [3] (summarized in Table 1 and illustrated in Fig. 1 ) is bistable in that if the initial concentrations of the caspases are smaller than the threshold values then this will lead to cell survival, otherwise lead to apoptosis. After carrying out sensitivity analysis (Table S1 in Supplementary Materials), the number of parameters that have an effective role in malfunctioning apoptosis was found to be ten. This leads to a large number of simulations (see Sect.
3.2) and therefore we have arbitrarily chosen four of them. To determine whether the system is robust to parameter variations i.e. insensitive to small changes in their numerical values, we obtained two additional parameter sets each representing cell model belonging to a healthy individual ( Table 2 ). These two additional parameter sets were obtained by changing the nominal parameters such that the bistable character of the cell is preserved. Therefore, each parameter set was bistable in response to apoptotic stimulus and hence represents cell model of healthy individuals. We also generated six parameter sets around each of the nominal parameter sets 1 and 3 to evaluate the statistical significance of the results for the two parameter sets ( Table S2) .
Assuming that a cell has a constant volume, is isothermal, homogeneous, and that each reaction is governed by mass action kinetics, the rate equations in the form of nonlinear ordinary differential equations can readily be obtained. These equations represent our model cell and are given in Bagci et al. [3] . Herein, we solved these equations numerically using the software XPPAUT developed by Ermentrout [36] for the simulation of the potential treatments. Here, we also include some terminology of nonlinear dynamical systems such as phase plane, nullclines, bifurcation diagrams, for easy reference [37] . A phase plane is a coordinate system in which, in this work, the axes are the concentrations of the proteins. A nullcline is the set of points where the derivative of a protein concentration with respect to time is zero. The intersection point of all the nullclines gives a steady state point of the system. Bifurcation is a qualitative change (such as bistable vs. monostable) in the system behavior when a control parameter value (in our work the inhibition rate constant k d ) changes. Figure 2a illustrates the phase plane of a bistable apoptosis model. The gray curves are the nullclines and their intersections are the steady state points. There are three steady states, denoted by (i), (ii) and (iii) which have zero, high and intermediate levels of executioner caspase-3 concentration. The steady state (i) is the cell survival state (zero executioner caspases-3 concentration), (ii) is the apoptotic state and (iii) is the cell fate decision point. The steady states (i) and (ii) are stable because a small perturbation away from them eventually disappears. On the other hand, the steady state (iii) is unstable because a small perturbation away from it grows either to cell survival (i) or apoptosis (ii). The two stable equilibrium points may bifurcate to one stable equilibrium point (i.e., monostability) if a system parameter (e.g., degradation rate of caspase-3) is changed. The phase plane in Fig. 2b is an example of this case where the monostable state is cell survival. A bifurcation diagram shows how a steady state changes as a control parameter varies [37] . In this bifurcation diagram given in Fig. 3 , the inhibition rate constant k d is the control parameter. When k d is in between the limit points (LP) LP1 and LP2 the system is bistable. On the other hand if k d is less than LP1 then monostable apoptotic state and if greater than LP2 then monostable cell survival state is achieved. After finding the steady states i, ii, and iii in the bifurcation diagram, a smooth function curve passing through the distinct points was obtained using the Kale-idaGraph Version 4.0 (Synergy Software). More is discussed about the bifurcation diagram in the Sect. 3.3.
Results and discussion
We first present the sensitivity of the steady state caspase-3 concentration to the parameters of the model given in Fig. 1 Mitochondria-dependent apoptotic pathways. Solid arrows denote chemical reactions or upregulation, lines terminated by a bar denote inhibition or downregulation, and dashed arrows depict translocation. The abbreviations used are; casp8, 9, 3: caspase-8, -9 -3; procasp9, 3: procaspase-9, -3; cyt c: cytochrome c X IAP 3.0 9 10 -2 nM/s 4.5 9 10 -2 nM/s 9.0 9 10 -2 nM/s X procaspase3 3.0 9 10 -1 nM/s 3.6 9 10 -1 nM/s 9.0 9 10 -1 nM/s X procaspase9 3.0 9 10 -1 nM/s 2.9 9 10 -1 nM/s 3.0 9 10 -1 nM/s X cytcmito 3.0 9 10 -1 nM/s 3.0 9 10 -1 nM/s 1.0 9 10 -1 nM/s Bagci et al. [3] and determine those that may induce a malfunction in apoptosis when perturbed from their nominal values. The list of chemical reactions and physical interactions in the model are given in Table 1 and is taken from Bagci et al. [3] . We, then, present the results for four hypothetical treatments that are obtained by simulating the model for three different parameter sets each representing a healthy cell. Different parameter sets refer to different cells which have different expression levels (or profiles), some of which could be caused by different genotypes. Finally, we compare the model predictions with experimental results compiled by di Pietro et al. [34] from databases.
Sensitivity analysis of mitochondria-dependent apoptosis model
To evaluate the sensitivity of caspase-3 concentration to the changes in model parameters, we used a simpler method than the one used by Shoemaker and Doyle [38] who have carried out sensitivity analyses on the parameters for the same model using tools from control engineering. However, the results of the two different approaches are in good agreement. Hereafter, the nominal values of the parameters are understood to be those given in Bagci et al. [3] and the steady-state concentration of caspase-3 for these parameters corresponds to 5.4 nM. For sensitivity analysis we increased and decreased the values of the parameters by 100-fold and then checked how much the steady-state value of [caspase-3] is changed from its concentration of 5.4 nM (baseline value in Fig. 4 ). The following parameters are found to be influential on the final steady-state concentration of caspase-3: initial p53 concentration ([p53]), the production rate constants of proapoptotic proteins, Apaf-1 (X Apaf1 ), procaspase-3 (X proc3 ), procaspase-9 (X proc9 ), Bid (X Bid ), Bax (X Bax ), mitochondrial cyt c (X cytcmito ), anti-apoptotic proteins Bcl-2 (X Bcl2 ), IAP (X IAP ), and the single degradation rate constant (k d ) for all the proteins. These parameters and the corresponding steady-state values of caspase-3 is given in Table S1 and shown in Fig. 4 . For example, if k d is increased by 100-fold from its nominal value of 0.006 s -1 , caspase-3 concentration is decreased to zero and if it is decreased by 100-fold, caspases-3 concentration increases to 4,827 nM (well above the threshold for apoptosis). Shoemaker and Doyle [38] also found that the steady-state concentration of caspase-3 is not sensitive to most of the parameters. Sensitivity analysis revealed not only the sensitive parameters but also whether an increase or decrease in these parameters may have an effect on the malfunction in apoptosis. We found that when the production rate constants of proapoptotic proteins are low, and the production rate constants of antiapoptotic proteins and the degradation rate constant of all proteins are high, then the model predicts monostability with the cell survival state being the only stable state (another justification of this statement can be seen in Figure S1 ). Therefore, the sensitivity analysis helped us to generate parameter sets for cells with malfunctioning apoptosis. These hypothetical malfunctioning cells are then treated in silico by four treatment types.
Hypothetical treatment
The roles of the sensitive parameters on malfunction in apoptosis and resistance to treatments in a hypothetical cell were then investigated. The robustness of the theoretical outcomes of the treatments were tested using simulations for three parameter sets representing three healthy cells (since each parameter set results in bistability). Parameter set 1 corresponds to that given in Bagci et al. [3] . Parameter set 2 was obtained by changing the numerical values of production rates of IAP (X IAP ), procaspase-9 (X proc9 ), procaspase-3 (X proc3 ) of set 1. Finally, parameter set 3 was obtained by changing the numerical values of production rates of IAP (X IAP ), procaspase-3 (X proc3 ) and mitochondrial cyt c (X cytcmito ) of set 1. These three parameter sets are given in Table 2 . We note that the numerical values of parameters in set 1 are close to those in the set 2 but are considerably different than those in set 3. The true values of these sensitive parameters are only known within a wide range. Even if we only take the upper and lower values of these ten sensitive parameters (i.e., design treatments at 2 levels), the number of in silico experiments to obtain all the main and interaction effects [39] which has to be carried out is large (2 10 = 1,024). Therefore, we took only four parameters out of ten and created set 2 and 3 by changing three of them at a time. Despite this, their predictions are qualitatively and quantitatively different. These three sets correspond to hypothetical healthy cells which may belong to three different individuals. We note that the gene expression levels of caspase-3, caspase-9 and cyt c are reported to vary naturally in human individuals in a database [40] . It is to be noted that the four sensitive parameters that we have chosen are among the most sensitive eight parameters found by Shoemaker and Doyle [38] .
In order to modify each of the three parameter set so as to obtain malfunctioning apoptosis, the numerical value of one of the sensitive parameters was changed and then checked for the presence of malfunction in apoptosis. If the result was on the affirmative, then we applied four potential treatments, one at a time to see if apoptosis could be achieved in this cell. To this end, the production rates of proapoptotic proteins were reduced to 1 and 15 % of their nominal values. These proapoptotic proteins were Apaf-1, procaspase-3, procaspase-9, Bid, Bax and mitochondrial cyt c. The criterion for malfunction in apoptosis in these phenotypes is either monostability (cell survival i.e., caspase-3 concentration is zero as shown in Fig. 2b ) in response to apoptotic stimulus or bistability whose apoptotic state has a caspase-3 concentration lower than the predetermined threshold value of 1 nM (only to be understood relatively). This concentration corresponds to approximately 2,500 molecules for a cell of diameter 20 lm. Note that when the production rates of proapoptotic proteins were reduced to 50 % of their nominal values, cell models with malfunction in apoptosis were predicted to be unattainable in all cases for parameter sets 1 and 2, and for parameter set 3 except for Bid deficiency, the cells had malfunction in apoptosis (data not shown We have also increased the production rates of antiapoptotic proteins Fig. 4 Results of sensitivity analysis. Steady state values of caspases-3 when the parameters are perturbed a k d , Apaf-1 production rate, IAP production rate, procaspase-3 production rate, procaspase-9 production rate, b Bid production rate, Bcl-2 production rate, Bax production rate, cyt c production rate, and p53 concentration. Black bars correspond to caspases-3 concentration when the relevant parameter is increased by 100-fold and white bars correspond to caspases-3 concentration when the relevant parameter is decreased by 100-fold. The dashed line correspond to caspases-3 concentration (5.4 nM) when the nominal parameter values are used namely, Bcl-2 and IAP. We observed malfunctioning only when we have increased the production rate by 400-fold.
The final value of the caspase-3 concentration was obtained as the steady-state solution of the governing differential equations using XPPAUT [36] . At the end of the simulation run, if it was found that the hypothetical cell is resistant to apoptosis, then we simulated the effect of the potential treatments which is described below. To this end, we made an appropriate change in a parameter to represent the effect of treatment and checked whether caspase-3 was produced. We assumed that the treatment becomes successful if caspase-3 concentration reached values greater than or equal to 1 nM. In those cells apoptosis may occur in a monostable fashion as well. This case was not investigated.
Using the sensitivity results given in Fig. 4 (Table S1 ), the following four different treatment methods that are also proposed by experimentalists were simulated to check whether apoptosis is induced (with a final caspase-3 concentration greater than or equal to 1 nM) in silico in a hypothetical malfunctioning cell:
1. Proteasome inhibitor treatment [41] (simulated by reducing the degradation rate constant (k d ) of proteins) 2. Bcl-2 inhibitor treatment [42] (simulated implicitly by decreasing the production rate constant of anti-apoptotic protein Bcl-2, and also by explicitly including Bcl-2 inhibitor into the model) 3. IAP inhibitor treatment [42] (simulated implicitly by decreasing the production rate constant of anti-apoptotic protein IAP, and also by explicitly including IAP inhibitor into the model) 4. Bid-like synthetic peptides treatment [43] (simulated by increasing the production rate of proapoptotic protein Bid)
The first treatment listed above which has the effect of reducing the degradation rate constants of the proteins might also have severe side effects because this treatment inhibits proteasomes that degrade proteins involved in pathways other than apoptosis as well and hence affecting the other functions of the cell. On the other hand, downregulating Bcl-2 and IAP and upregulating Bid might have less severe side effects. The predictions of the outcomes of those four potential treatments are discussed below and the results are presented in Fig. 5 , Tables 3, 4 , 5 and S4, S5. In all the simulations, the same amount of initial caspase-8 concentration was used in comparing the drug effects.
Possible outcomes of proteasome inhibitor treatment
Herein we checked whether apoptosis is achieved in a hypothetical malfunctioning cell (cell model whose steady-state concentration of caspase-3 is \1 nM). For this purpose, as a treatment, we reduced the degradation rate constant of proteins (k d ) to achieve apoptosis. Rate constant k d can be reduced biochemically by using a proteasome inhibitor [41] . The preclinical studies have shown that proteasome inhibitor bortezomib induces apoptosis, and overcomes chemoresistance in several malignancy models both in vitro and in vivo [44] . As the proteins are degraded by the same proteasome machinery, we have taken all the degradation rates of the proteins to be equal to k d (0.006 s -1 as an approximate value) and decreased this value to see if caspase-3 concentration exceeds the threshold value of 1 nM to mimic the effect of proteasome inhibitor. For a hypothetical malfunctioning cell, the range of k d values within which apoptosis is possible is given in Fig. 5 and the numerical values are given in Table 3 . It is observed that as k d value decreases, the steady-state caspase-3 concentration increases in the present theoretical results. This functional relation is investigated using the steady-state concentration of caspase-3 versus k d graph and is given in Fig. 3 . The parameter set 1 is used in the rate equations except for the Apaf-1 production rate which is decreased by a factor of 100-fold (upper left entry in Table 3 ) to create a hypothetical malfunctioning cell. Apoptotic response is monostable apoptosis when k d was less than the limit point 1 (LP1) (k d = 0.006 9 0.07 s -1 ) or monostable cell survival when k d was greater than the limit point 2 (LP2) (k d = 0.006 9 0.48 s -1 ) and bistable when k d is in between this interval (0.006 s -1 is the nominal value of k d ). For the bistable case, whether the response is cell survival or apoptosis depends on the concentration of the caspase-3 protein. The upper solid curve in Fig. 3 represents the apoptotic steady state, the dashed curve in the inset represents the unstable steady state (a slight increase in caspase-3 concentration will lead to apoptosis, whereas, a slight decrease will lead to cell survival) and the horizontal lower solid line represents the cell survival steady state. The inset is the enlargement of the lower part of the diagram which is invisible due to scaling. The points for steady states which were simulated are shown in circles and the smooth function curves were obtained. The caspase-3 concentration (6.7 9 10 -3 nM) predicted for the k d value at LP2 was too low for the inception of apoptosis. Therefore, in Table 4 , we tabulated the range of k d values for which caspase-3 steady state concentration is above the assumed threshold value of 1 nM which is obtained when k d is smaller than or equal to 0.006 9 0.35 s -1 . The same procedure was repeated to fill in the rest of the entries in Table 3 . The case when k d \ LP1, i.e., the cells are monostable apoptotic, was not investigated.
In this study, inhibition of proteasomes (simulated by reducing k d ) was found to induce apoptosis in hypothetical malfunctioning cells. Experimental studies also suggest that proteasome inhibitors can be used for inducing apoptosis [41] . However, it should be noted that the present study does not take into account the inhibition of proteasomal degradation of IKB and subsequent inhibition of NF-KB which can change the production rates of proteins in the apoptotic pathways [45] .
It can be seen in Table 3 that the overall proapoptotic protein degradation rate has to be decreased in different proportions for each proapoptotic protein deficiency and for each antiapoptotic protein overproduction. It should be noted that the antiapoptotic overproduction has to be increased by 400-fold to yield malfunctioning. If the production rates of antiapoptotic proteins are increased by 10or 200-folds, then in most cases we have obtained healthy cells. This difference may help to determine the amount of proteasome inhibitor needed to treat a patient. For a healthy cell, it is assumed that apoptosis is possible when k d is less than or equal to 0.006 s -1 [3] . When the Apaf-1 production rate in cell model is reduced by 100-fold, while keeping the other protein production rates at their nominal values, apoptosis is then possible for k d range between 0 and 
Deficiency in proapoptotic protein (nominal value multiplied by a factor)
Parameter set 1 Parameter set 2 Parameter set 3 X Apaf-1 9 0.01 0 -L* 9 0.35 0 -L 9 0.35 0 -L 9 0.27 X procaspase-3 9 0.01 0 -L 9 0.31 0 -L 9 0.33 0 -L 9 0.53 X procaspase-9 9 0.01 0 -L 9 0.42 0 -L 9 0.43 0 -L 9 0.50 X Bid 9 0.01 0 -L 9 0.88 0 -L 9 0.89 0 -L 9 0.79 X Bax 9 0.01 0 -L 9 0.42 0 -L 9 0.42 0 -L 9 0.36 X cytcmito 9 0.01 0 -L 9 0.35 0 -L 9 0.35 0 -L 9 0.27 X Bcl2 9 400 0 -L 9 0.33 0 -L 9 0.32 0 -L 9 0.26 X IAP 9 400 0 -L 9 0.96 0 -L 9 0.93 0 -L 9 0.75 X Apaf-1 9 0.15 0 -L 9 0.78 0 -L 9 0.79 0 -L 9 0.62 X procaspase-3 9 0.15 0 -L 9 0.95 0 -L 9 0.97 0 -L 9 0.90 X procaspase-9 9 0.15 0 -L 9 0.91 0 -L 9 0.93 0 -L 9 0.81 X Bid 9 0.15
Healthy cell Healthy cell 0 -L 9 0.97 X Bax 9 0.15 0 -L 9 0.94 0 -L 9 0.94 0 -L 9 0.81 X cytcmito 9 0.15 0 -L 9 0.78 0 -L 9 0.79 0 -L 9 0.62 X Bcl2 9 200 0 -L 9 0.43 0 -L 9 0.43 0 -L 9 0.34 X IAP 9 200
Healthy cell Healthy cell Healthy cell X Bcl2 9 10
Healthy cell Healthy cell 0 -L 9 0.85 X IAP 9 10
Healthy cell Healthy cell Healthy cell 0.006 9 0.35 s -1 . When the Bid production rate in cell model is reduced by the same amount, apoptosis can be achieved if k d range is 0-0.006 9 0.88 s -1 . Therefore, the amount of proteasome inhibitor which should be used for the treatment of a patient with Apaf-1 deficiency may be more than a patient with Bid deficiency according to the present model. To know the least amount of drug that is effective is important to reduce its side effects. When we analyzed the consequences of Bid deficiency in people whose Bid production rate is reduced to 15 % of its nominal value, we found that the cells represented by parameter sets 1 and 2 are healthy. However, the cell represented by parameter set 3 have malfunction in apoptosis. This is expected since the k d ranges are similar in parameter sets 1 and 2 but are significantly different in parameter set 3. It is imperative to demonstrate that the contrast between set 1 and 3 given in Table 2 do not just reflect statistically insignificant random variations around their mean values. To check whether variations in four proteins' (IAP, procaspase-3, procaspase-9 and mitochondrial cyt c) production rates produce statistically significant outcome, we have, using normally distributed random numbers, generated six parameter sets by varying the parameters in set 1 and 3 (these are given in Table S2 ). Note that the parameter set 2 is not included for it is similar to the parameter set 1. We have carried out the same calculations given in Table 3 for the randomly generated parameter sets in Table S2 and thereby obtained Table S3 . For each hypothetical deficiency in the production levels of the pro-apoptotic proteins (column 1 in Table S3 ), 90, 95, 99 % CI for the difference in the means of the two hypothetical populations of the parameter sets 1 and 3 are calculated and shown in Fig. 6 (The numerical values of the confidence intervals are given in Table S3 ). When the production rates of proapoptotic proteins are decreased by 100-fold, we found that the difference in the means is statistically significant for Apaf-1, procaspase-3 and procaspase-9 as these do not change sign within their confidence intervals. On the other hand, for Bid, Bax and mitochondrial cyt c, confidence intervals change sign and hence their differences in the means are not statistically significant, i.e., they can also be zero. When the production rates are decreased by 15 %, some of the deficiencies did not lead to unhealthy cell models and hence no confidence interval is calculated for that group. For those that we have calculated all the confidence intervals is found to include zero. If the production rates of Apaf-1 or procaspase-3 or procaspase-9 suffer a drastic reduction down to 1 % of their base values, then the statistical results suggest that parameter set 1 group require different doses of proteasome inhibitor compared to the individuals whose cells can be represented by parameter set 3. In this study, we did not assess the degradation of proteins by lysosomes as this will simply shift the steady state concentrations of all the proteins in the cell downwards.
Possible outcomes of Bcl-2 and IAP inhibitors treatments
In the previous treatment method, we determined the proapoptotic proteins whose deficiencies or antiapoptotic proteins whose overproductions may result in hypothetical malfunction. To simulate treatments, we then reduced the antiapoptotic Bcl-2 and IAP production rates to induce apoptosis in these hypothetical malfunctioning cells (Tables 4, 5 ). The effective concentrations of Bcl-2 and IAP can be reduced biochemically by introducing their inhibitors into the medium [42] . Such an inhibitor for Bcl-2 is obatoclax mesylate (GX015-070) [42] and for IAP is small compounds derived from SMAC peptide [42] . In the simulation studies we have reduced the effective protein concentrations i) implicitly by reducing the corresponding rate constants since if three proteins are synthesized and one of them is inactivated by an inhibitor which binds irreversibly, then the production rate of the functional protein will be reduced by one third, and ii) explicitly by using an inhibitor which competitively binds to its receptor. The outcomes of treatment methods for the hypothetical malfunctioning cells wherein Bcl-2 and IAP inhibitors are introduced implicitly as an in silico treatment are summarized in Tables 4 and 5 , respectively. For the cells whose caspase-3 concentration exceeds the threshold value of 1 nM, no treatment is needed (denoted by ''Healthy cell'' in the Tables). On the other hand, when the cells are malfunctioning then whether the in silico treatment induces apoptosis depends on the parameter set and proapoptotic protein deficiency. Reducing the production rates of Bcl-2 or IAP may induce apoptosis. To achieve this, the amount of reduction in the production rate of Bcl-2 to induce apoptosis (IAP inhibitor treatment does not induce apoptosis, this is because SMAC/DIA-BLO is missing in our model which renders IAP less effective.) is given in Table 4 . Apoptosis is assumed to be achieved if the caspases-3 concentration exceeds its threshold value. For example, in Table 4 for parameter set 1, when Bax concentration was reduced to 15 % of its nominal value, apoptosis was possible if the production rate of Bcl-2 was reduced to values smaller than 3 9 10 -2 9 0.10 nM/s (note that for a healthy person Bcl-2 formation rate was assumed to be equal to 3 9 10 -2 nM/s-Bagci et al. [3] ). This simulation predicts sensitivity to treatment. If the hypothetical malfunctioning cells do not undergo apoptosis even with zero production rates of Bcl-2 and IAP, then this case is presented as ''Apoptosis impossible (denoted by x)'' in the Tables 4 and 5 . For these cases, the steady-state caspase-3 concentration was either zero, or equal to a value smaller than 1 nM and the corresponding hypothetical malfunctioning cells are referred to as being resistant to treatment. For example, in Table 4 and for the parameter set 1, when the production rate of procaspase-3 is 15 % of its nominal value, steady state caspase-3 concentration is 0.80 nM and hence resistant to treatment.
The results for parameter sets 1 and 2 presented in Tables 4 and 5 show that an individual with a Bax production rate reduced to 15 % of its nominal value could be successfully treated by a Bcl-2 inhibitor but not by an IAP inhibitor. Also, Bcl-2 inhibitor therapy can only be effective on people with Bax deficiency but not on others. The reason for Bcl-2 inhibitor being effective on Bax deficiency is possibly because of the fact that Bcl-2 directly interacts with Bax. When Bcl-2 inhibitor treatment is employed for the cases whose proapoptotic protein production rates are reduced to 1 % of their nominal values, then, no variations are detected between the groups of parameter set 1 and 3 and also within the groups of each set (Table 4 ). However, some differences are observed when the production rates are reduced to 15 % of their nominal values for Bax production deficiency.
Thus far, we have discussed the cases when antiapoptotic inhibitor treatment was employed implicitly. As was mentioned previously, we obtained unhealthy individuals (i.e., individuals with malfunction in apoptosis) when we have increased the production rates of Bcl-2 and IAP by 400-fold. This function cannot be restored by using Bcl-2 inhibitor if IAP was overproduced or using IAP inhibitor if Bcl-2 was overproduced. On the other hand, if Bcl-2 (IAP) is overproduced, Bcl-2 (IAP) inhibitor restored apoptosis (See Tables S4 and S5 ).
Possible outcomes of Bid-like synthetic peptides treatment
In order to induce apoptosis in hypothetical malfunctioning cells, we then increased the production rate of Bid in the parameter sets by threefold. The introduction of Bid-like synthetic peptides into the cells by endocytosis can be mimicked by increasing the Bid production rate. [43] . Apoptosis was not possible in response to Bid-like synthetic peptides treatment for all the parameter sets even though the production rate of Bid was increased by 20-fold (data not shown). 
Cell variability
Cell variability can be in genotype and phenotype. We have obtained the phenotype variability in cells of the same type by varying the initial protein concentrations using a Gaussian random variable around their mean value. We have taken the standard deviation of these random variables as 50 % of their mean values and run 50 experiments all of which resulted in apoptosis, i.e., cell to cell variation is found to have no effect on apoptosis. On the other hand, for the initial condition of pro-apoptotic caspase-8, internally (intracellularly) produced and activated by an external death stimulus, we found a critical initial concentration value at which about half of the in silico experiments resulted in cell survival. As long as the initial value of caspase-8 concentration is above this critical value, then, regardless of the initial concentrations of the other proteins, the cell will undergo apoptosis and cell survival if below. In other words, the model is robust to variations in the initial conditions (phenotypic variations of the hypothetical cells with the same genotype) if the initial concentration of the caspase-8 is above (apoptosis) or below (cell survival) a critical value. In our work, the genotypic variability is represented by the variability between, for example, the parameter set 1 and 3. Because the protein degradation rate constant k d value is smaller in parameter set 3 than set 1, this set shows more susceptibility to malfunction in apoptosis (Table 3 first row 0.35 vs. 0.27). As a result, higher doses of medication may be required for the treatment of this hypothetical case. When we randomly varied the initial conditions of these two parameter sets, we observed that the apoptotic responses are insensitive to cell variability. This result shows that the responses of the three sample cells are insensitive to cell variability. It is to be noted that this result is the outcome of the deterministic mass action kinetics assumption. However, Scaffidi et al. [46] observed that there is cell-to-cell phenotypic variability in the response to death ligands among cells of the same type. This experimental observation is an indication of stochasticity in the same cell types. On the other hand, in the simulations of stochastic chemical reactions using Gillespie algorithm, we have found that the bistability present in the deterministic case is lost when stochastic algorithm is used and hence not carried out any further.
Comparison of theoretical results with experiments
Di Pietro et al. [34] conducted an extensive study on Genomics, Transcriptomics, Proteomics, Interactomics, Oncogenomics, and Pharmacogenomics of Apoptotic Machinery in humans. They report mRNA levels of proteins in apoptotic machinery in normal and cancer cells for 13 cancer types. We compared their findings related to transcriptomics of apoptotic machinery with our theoretical predictions. They utilized the data available in Human Transcriptome Map, NCI60 Cancer Microarray Project and Oncogenomics for cancer and normal tissues [47] [48] [49] . The authors reported the upregulation and downregulation of gene expression when the gene is up or downregulated by at least threefold in a cancer tissue compared to a normal one. Accordingly, we increased or decreased the protein expression rates that are present in our model by at least threefold in the simulations and checked whether apoptosis can be induced with enough caspase-3 activation. The results are summarized in Table 6 where column number 1 lists 13 different cancer types, column numbers 2-7 list the change in the levels of mRNA of proteins which are present in our model (extracted from Fig. 7a in their paper) Fig. 7a ). For example, for ovary cancer, caspase-3 concentration level predicts cell survival (0.9 nM) which corresponds to casp9, Bcl-2, Bid and Apaf-1 expression rates remaining constant and increasing Bax by threefold in cancer cells compared to normal cells. Only when caspase-3 expression rate is decreased by 85 % (0.15x), we get cell survival. Among those 13, our theoretical results predict apoptosis malfunctioning in six cancer types. Interestingly, out of seven types that we failed to predict apoptosis malfunction, the three cancer types (pancreas, skin, thyroid cancers) have mutations in BRAF, CDKN2A and TP53 genes (the remaining ten cancers do not have these mutations) that are either not included (BRAF, CDKN2A) or not represented adequately (TP53, data not shown) in our model. These theoretical results suggest that the transcription of these three genes should be included in a model for simulation of cellular malfunction related to malignancy.
Conclusion
We have used an ODE model composed of 31 dependent variables obtained from mass-action kinetics with 52 parameters most of which are coming from the kinetics of the reactions. Out of these 52 parameters, caspase-3 concentration is found to be sensitive to 10 of them. A subset of these parameters is changed to generate 3 hypothetical healthy cells manifesting bistability. These parameters are further changed to generate cell models representing hypothetical malfunctioning cells. These hypothetical cells are then subjected to four different in silico treatment methods. The proteasome inhibitor treatment may be considered to be the most effective one compared to other treatment methods as this restores apoptosis in the cells for all proapoptotic protein deficiencies and antiapoptotic protein overproductions. On the other hand, in the treatment methods involving Bcl-2 and IAP inhibitors, and Bid upregulation, only some of the proapoptotic protein deficiencies or antiapoptotic protein overproductions may be treated. Consequently, depending on the type of the treatment and the identity of the deficient proapoptotic protein, or the overproduced antiapoptotic protein apoptosis may not be induced in a hypothetical malfunctioning cell. It is to be noted that the response to treatments is studied by considering malfunction only in apoptosis but not in other pathways such as multi drug resistance gene pathway. We speculate that the simulation results suggest that molecular heterogeneity (genotype variation) in patients' cells can be a reason for different treatment consequences.
The results imply that the targeted treatments on one protein only i.e., Bcl-2 and IAP inhibitor treatments and Bid-like synthetic peptide treatment are not very effective except when the problem is in the targeted protein. For example, Bcl-2 inhibitor treatment will very likely restore apoptosis in a malfunctioning cell with a defect in its Bcl-2 protein but not on any other proteins. On the other hand, proteasome inhibitor treatment may be much more efficient since this affects all of the proteins in the model. This hypothesis remains to be tested by experiments. Another hypothesis to be tested by experiments which is raised in this study is that a treatment is not likely to be effective if the target protein is not close to the problematic protein in the sequence of reactions/interactions in the pathway. A close collaboration between experimentalists and theoreticians may be useful to test the hypotheses arising from computations which will in turn improve the models to generate new hypotheses [50] .
It is to be noted that out of ten parameters that are found to be sensitive to caspase-3 production, only three out of four randomly chosen parameters are varied. However, this small subset of parameter variations resulted in qualitative differences in all therapy methods and quantitative differences in proteasome inhibitor therapy method. We conjecture that the combined studies of computations and experiments may facilitate the decision of which chemotherapy drug or combinations of drugs can be used when treating patients with known cancer biomarkers.
